CLGN CLGN
Company Profile ↓Company Overview
CLGN (CLGN) is a publicly traded company listed on with a market capitalization of $3.97M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 99.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $2.37M (+360.4% YoY); net profit $-11.49M.
- Trailing 12 Months Year-on-year growth — revenue +360.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 99.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 99.41% |
| 1 Year: | 360.39% |
Stock Price Performance
| 1 Year: | -86.21% |
| 6 Months: | -81.54% |
| 3 Months: | -22.48% |
| 1 Month: | -13.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.02 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 99.4% over 5 years.
CONS
- Trading 90.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 2.06M | 179.00K | 77.00K | 60.00K | 73.00K |
| Cost of Revenue | - | 188.00K | 186.00K | 269.00K | 192.00K | 316.00K |
| Gross Profit | - | 1.87M | -7.00K | -192.00K | -132.00K | -243.00K |
| Operating Expenses | - | 3.52M | 3.17M | 3.31M | 3.02M | 2.87M |
| Operating Income | - | -1.65M | -3.18M | -3.51M | -3.15M | -3.12M |
| EBITDA | - | -1.40M | -2.95M | -3.28M | -2.93M | -2.90M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -1.45M | -3.35M | -3.48M | -3.21M | -3.10M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -1.45M | -3.35M | -3.48M | -3.21M | -3.10M |
| Diluted EPS | - | -0.13 | -0.28 | -0.27 | - | -0.23 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 299.00K | 10.96M | 515.00K | 2.37M |
| Cost of Revenue | 400.00K | 1.99M | 1.62M | 835.00K |
| Gross Profit | -101.00K | 8.97M | -1.11M | 1.54M |
| Operating Expenses | 17.00M | 16.48M | 16.14M | 13.02M |
| Operating Income | -17.10M | -7.51M | -17.25M | -11.48M |
| EBITDA | -16.02M | -6.41M | -16.21M | -10.57M |
| Interest Expense | - | - | - | - |
| Pretax Income | -16.93M | -7.02M | -16.61M | -11.49M |
| Tax Provision | - | - | - | - |
| Net Income | -16.93M | -7.02M | -16.61M | -11.49M |
| Diluted EPS | -1.53 | -0.62 | -1.45 | -0.94 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 37.77M | 34.13M | 18.71M | 10.79M |
| Current Assets | - | 31.66M | 28.02M | 13.18M | 6.75M |
| Cash & Equivalents | - | 29.65M | 26.67M | 11.91M | 5.59M |
| Inventory | - | 1.43M | 714.00K | 440.00K | 573.00K |
| Receivables | - | 9.00K | 0 | 150.00K | 1.00K |
| Total Liabilities | - | 5.49M | 5.79M | 5.25M | 4.70M |
| Current Liabilities | - | 3.10M | 3.25M | 2.97M | 2.67M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 2.91M | 3.16M | 3.08M | 2.85M |
| Total Equity | - | 32.28M | 28.34M | 13.46M | 6.08M |
| Shares Outstanding | - | 11.19M | 11.47M | 11.47M | 12.82M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -13.70M | -2.76M | -14.09M | -9.42M |
| Investing Cash Flow | - | 28.92M | -1.16M | -539.00K | -27.00K |
| Financing Cash Flow | - | 1.87M | 1.11M | 9.00K | 3.10M |
| Capital Expenditure | - | -1.32M | -954.00K | -483.00K | -28.00K |
| Free Cash Flow | - | -15.01M | -3.72M | -14.58M | -9.45M |
| Net Change in Cash | - | 17.10M | -2.81M | -14.62M | -6.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | -33.8% | 81.8% | -215.5% | 64.8% |
| Operating Margin % | -5,718.1% | -68.5% | -3,349.7% | -484.3% |
| Net Margin % | -5,660.5% | -64.0% | -3,225.0% | -484.6% |
| ROE % | -52.4% | -24.8% | -123.3% | -188.9% |
| ROCE % | -49.3% | -24.3% | -109.6% | -141.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLGN
Loewenbaum group holds 33% CollPlant (CLGN) stake after warrant deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQeDQzNUIzLTNCdF80NGJzTWhYRlNsZFRIQzVXTm9NOVI3Zm9KZEZkcVV6aUVObHJ5ZjhVZkRpZm1DZzduYnAwQkxGZEFCM1ZicWVHLW5Jak1KSW13V3lYaVpzdVB1aUU4bUU5WEdXbU9vdGhnbUFSVjRPZjJvcHZNeHRQLTZpZUM5MVBPal…
CollPlant Shareholders Approve Proposal at Extraordinary General Meeting - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxQbnlzTFBPWE5pNGhCa0ppaHpWbVdzSExVVlVEVUZEem9Xd0kzbWpkSTJ6a2tMQnJscVNnWkVpY0tXcEF3QTBVQ0VmWXBjMFFIVUwzM29SR3ZRSVRuYzB1UGcwNG93MzN2NzJvb1g4cE5Na1d0NHYzdHhPcldjeWhGN1hZRlZQd0stTk9ES1…
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPd2xYSElOcVJzNkdrYVdERHpmX3NzNkMyODNuQ1dOV0VCUUlyX1k4NkVlN0lYbFhRR0ptd1ZLQndvMXBjVEZ3bWstUE9VRGZfNURSdE5zcUk1dUhJVTNpNFRLVjFSNC1IN1YzRDhsbUNraHctWnZvNUppcmNwdDZXYzR0SlM1TThSeGIxQT…
CollPlant Biotechnologies Ltd. Revenue Breakdown – NASDAQ:CLGN - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5RQVpqeEhxcG5MRjhyemVGbnJFNWlWV1Z1V1lzUGlTYlp3SUFjTmRTMFNwRV9lUEZpajFKQmxVRUFIcnNwVmd6WGFWMWVBVWdkR3VvMGEtSlcxTFE5S3c2dFFjaUNPYTRKZThCcEtUbXRFUEd6cDM0?oc=5" target="_blank">CollPla…
CLGN|Collplant Biotechnologies Ltd|Price:0.328|Chg%:+0.001 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFA2eG9ZOTJySTBCUWNUd2pzU1ZjMDRrYUprLU5EOXBIaFB5SndZZDhnSVhtVWFrbl85Q2FOWGxZOXI1OGNJQzJqV2ZDUTFCekphOXF6OXlQSklidGxkMXhnWkJDdkFSc243YUsxRktR?oc=5" target="_blank">CLGN|Collplant Biot…
CollPlant Biotechnologies (NASDAQ: CLGN) reverse split to boost share price - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOU042bkRxMHh5SHZ3LXJIMWhvaE40cTFNUzVIZkdhcWZERDd2ZHZxZjZWa2VjeWY4NzZwWE0zX3l4M3drU0FWVWFCRVgwVmpFcmJFSUlHXzVuNWI4RTFaaFN6RTRNSHRxWGwteWZ4THBhUmVpZ2ZNYmhiVkt6VmhZUDJNZkk3LUkzaTRSWE…
CLGN — Frequently Asked Questions
What is the current share price of CLGN?
As of 2026-08-05 17:25 PDT, CLGN trades at $0.31 on NASDAQ/NYSE. Its 52-week range is $0.27 to $3.15.
What is the market capitalisation of CLGN?
CLGN has a market capitalisation of $3.97M on NASDAQ/NYSE.
What is the P/E ratio of CLGN?
CLGN trades at a trailing price-to-earnings (P/E) ratio of -0.33. Its price-to-book (P/B) ratio is 0.65.
Is CLGN a good stock to buy?
This page provides a data-driven analysis of CLGN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.